

September 3, 2016

Dear Editor,

Please find enclosed the edited manuscript Word format (file name: 1 28751-Revised Manuscript).

**Title:** Bevacizumab and GI bleeding in hereditary hemorrhagic telangiectasia

**Authors:** George Ou, Cherry Galorport, Robert Enns

**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**ESPS Manuscript NO.:** 28751

The manuscript has been improved according to the suggestions of the reviewers/editors:

Reviewer Comments:

1. The introduction has been clarified to state that bevacizumab has reported utility in managing complications of HHT. We have also incorporated a description of bevacizumab in the same sentence.
  - a. "Since the discovery of elevated vascular endothelial growth factor (VEGF) expression in patients with HHT[1], reports of bevacizumab, a monoclonal antibody against VEGF, in managing complications of HHT have emerged"
2. We also edited the text as per reviewer's suggestion, including changing the case report to past tense.

Thank you for reviewer's feedback and suggestions. We appreciate the opportunity to publish our case report in the *World Journal of Gastrointestinal Surgery*.

Sincerely,

George Ou, MD

Department of Medicine, Division of Gastroenterology

St. Paul's Hospital, University of British Columbia

770 - 1190 Hornby Street

Vancouver, B.C. V6Z 2K5

Tel: +1-778-223-2181

Email: ougeorge@gmail.com